PDS Biotechnology Release: CEO Frank Bedu-Addo Presenting at BIO 2016

  • PDS Biotechnology Release: CEO Frank Bedu-Addo Presenting at BIO 2016

    North Brunswick, NJ:  PDS Biotechnology, a private clinical stage immuno-oncology company developing novel immunotherapies, announces that CEO Frank Bedu-Addo will make a presentation at BIO 2016, being held at the Moscone Center, 747 Howard Street, San Francisco, California from June 6-9 2016.

    The presentation will be held in Theater 1 on Tuesday, June 7, commencing at 2:15pm, and provide information on the positive safety and CD8 + T-cell induction results from the PDS0101 Phase 1 human clinical trial.  PDS0101 is the company’s lead program based on its proprietary Versamune® T-cell activating platform.  Dr. Bedu-Addo will discuss the unique combination of human safety and T-cell potency and its impact on enhancing the development of effective immunotherapies for cancer.  The talk will also cover PDS’ plans for upcoming Phase 2 clinical trials in several HPV-related cancers, as well as other cancers including prostate, ovarian, breast and colorectal cancers.

    The BIO convention brings together over 15,000 biotechnology and pharma leaders, covering a wide spectrum of life sciences areas including drug discovery, bio-manufacturing, genomics and more.

    About the Versamune® T-Cell Activating Platform:

    Versamune® is a synthetic T-cell activating nanotechnology that overcomes a key obstacle facing cancer immunotherapy by facilitating efficient access of cancer protein antigens to pathways that enable their effective presentation to killer T-cells.  This process trains the body’s T-cells to recognize and efficiently attack the cancer.  The ingredient of the Versamune® platform has also been proven to activate critical immunological signaling pathways that result in the safe production of immunological proteins known as cytokines and chemokines locally within the lymph nodes to recruit T-cells, and enhance T-cell proliferation as well as the killing activity of T-cells.  Activation of these immunological pathways may also be responsible for the ability of the Versamune® -based immunotherapies to reduce the population of immune suppressive cells and to facilitate the killing activity of the T-cells specifically within the tumors.

    About PDS Biotechnology:

    PDS Biotech is a clinical stage immuno-oncology company committed to the development of simpler, safer and more effective immunotherapies.  An example of the company’s approach is the Versamune® T-cell activating platform, the first immuno-oncology technology to successfully combine the three critical attributes of effective immunotherapies in a simple nanoparticle, while also eliminating the potentially debilitating toxicities of some of the leading immunotherapy approaches.  PDS Biotechnology’s oncology pipeline includes products for prostate, ovarian, breast and colorectal cancers, in addition to its lead PDS0101 program for several HPV-related cancers.

    Contact Details

    PDS Biotechnology Corp.

    Frank Bedu-Addo, Ph.D., CEO

    Michael King, M.B.A., CFO

    Phone: +1-732-640-0145

    Email:  Execinfo@pdsbiotech.com

    PDS-Biotech

    Comments are closed.